Last reviewed · How we verify
Anti-HBV antiviral prophylaxis
Anti-HBV antiviral prophylaxis prevents hepatitis B virus infection or reactivation by inhibiting viral replication through antiviral mechanisms.
Anti-HBV antiviral prophylaxis prevents hepatitis B virus infection or reactivation by inhibiting viral replication through antiviral mechanisms. Used for Hepatitis B virus prophylaxis, Prevention of HBV reactivation in at-risk populations.
At a glance
| Generic name | Anti-HBV antiviral prophylaxis |
|---|---|
| Also known as | tenofovir disoproxil fumarate |
| Sponsor | Institut de Recherche pour le Developpement |
| Drug class | Antiviral agent |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
This prophylactic treatment is designed to prevent hepatitis B virus (HBV) infection or suppress viral replication in at-risk populations or those with chronic HBV. The specific mechanism likely involves nucleos(t)ide reverse transcriptase inhibitors or other antivirals that target HBV polymerase to reduce viral load and transmission risk.
Approved indications
- Hepatitis B virus prophylaxis
- Prevention of HBV reactivation in at-risk populations
Common side effects
- Lactic acidosis
- Hepatotoxicity
- Nausea
- Fatigue
Key clinical trials
- Antiviral Prophylaxis and Infant Vaccination to Prevent Perinatal Hepatitis B Infection (PHASE3)
- Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants (PHASE2)
- Detecting Occult HBV Infection in Liver Donors Positive for Antibody to Hepatitis B Core Antigen (Anti-HBc) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: